Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | June 21, 2026 | June 23, 2026 |
| Verona Pharma plcVRNA · Entity 74409 | Director | August 09, 2021 | August 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 21, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-20 | Direct | 4,200 |
Reported balance
After 2026-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-21 · Grant · Acquired 4,200 · Balance 4,200 F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Verona Pharma plc
Report date August 09, 2021 · Filed August 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08 | Direct | 64,000 |
Reported balance
After 2021-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-09 · Grant · Acquired 64,000 · Balance 64,000 F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 10,491 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.55 · Expires 2028-12-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 1,333 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2029-06-10 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 823 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.15 · Expires 2030-05-18 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Disposition to issuer · Disposed 635 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.60 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.30 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-18 · Disposition to issuer · Disposed 2,124 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2033-05-26 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 1,314,127 · Balance 0 F3: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the "Merger Agreement"), between Sierra Oncology Inc. (the "Issuer"), GlaxoSmithKline plc ("GSK"), and Orikum Acquisition Inc. ("Acquisition Sub"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes. F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2029-11-29 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 1,500 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F6: The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 6,874 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F7: The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series A Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2024-11-13 | IndirectSee footnotes | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 871,125 · Balance 0 F9: At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the "Series A warrants") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants. F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F3: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the "Merger Agreement"), between Sierra Oncology Inc. (the "Issuer"), GlaxoSmithKline plc ("GSK"), and Orikum Acquisition Inc. ("Acquisition Sub"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes.
F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP.
F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F6: The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger.
F7: The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger.
F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option.
F9: At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the "Series A warrants") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2022 Filed Feb 1, 2022 22:04 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherSeries B Warrants (right to buy) · Derivative | 287,471 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0000905718-22-000178 · sierraonco_fm4jan282022.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 287,471 shares Expires not disclosed F3 · derivative.expiration_date: Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:04 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock, $0.001 par value | 287,471 | $13.20 | $3,794,617.20 |
DisclosureSEC source: 0000905718-22-000178 · sierraonco_fm4jan282022.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,164,127 F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | PurchaseCommon Stock | 500,000 | $14.00 | $7,000,000.00 |
DisclosureSEC source: 0000905718-21-001587 · adicetbio_fm4dec82021.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,140,721 F1 · ownership.nature: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP ("Abingworth GP 8"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 08, 2021 Filed Dec 13, 2021 23:00 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | PurchaseCommon Stock | 500,000 | $14.00 | $7,000,000.00 |
DisclosureSEC source: 0000905718-21-001591 · adicetbio_fm4amdec82021.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,115,385 F1 · ownership.nature: The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP ("Abingworth GP 8"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:42 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-21-102888 · tm2124631-2_4seq1.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Ordinary Shares · 64,000 shares Expires 2031-08-08 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 14:24 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right To Buy) · Derivative | 6,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039087 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date. F2 · ownership.direct: The Reporting Person is a Partner of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VII, LP ("ABV VII"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of ALLP. F3 · ownership.direct: ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 01, 2021 Filed Jun 4, 2021 20:29 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 31,862 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000899243-21-022038 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,862 Underlying: Common Stock · 31,862 shares Expires 2021-06-01 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:26 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 8,172 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-21-030102 · doc4.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,172 Underlying: Common Stock · 8,172 shares Expires 2031-04-29 F2 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning March 2, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:26 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-21-030102 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:18 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0000899243-21-009877 · doc4.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,828 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F3 · derivative.exercise_date: 33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| March 02, 2021 Filed Mar 16, 2021 23:07 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0000899243-21-012024 · doc4a.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,828 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F3 · derivative.exercise_date: 33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 02:41 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-21-001764 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021). Read SEC document |
| June 26, 2020 Filed Jul 6, 2020 20:03 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 3,333,330 | $1.65 | $5,499,994.50 |
DisclosureSEC source: 0000905718-20-000724 · ownership.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,302,602 F1 · ownership.nature: Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP, F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:05 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy · Derivative | 6,874 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0000905718-20-000564 · sierraonco_fm4jun92020.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Underlying: Common Stock $.001 par value · 6,874 shares Expires 2030-06-09 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 9, 2020, with 100% of the total shares vested and exercisable on June 9, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 9,530 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0000899243-20-013720 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,530 Underlying: Common Stock · 9,530 shares Expires 2030-05-18 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionSeries A Convertible Voting Preferred Stock · Derivative | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-000098 · sierraonco_fm4jan292020.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 871,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F5 · shares: Consists of 11,500 shares of Series A Preferred Stock held by ABV VII which are convertible into an aggregate of 871,125 shares of Common Stock, as adjusted for the Reverse Split. F3 · price: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · derivative.exercise_date: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · derivative.expiration_date: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionCommon Stock | 871,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000098 · sierraonco_fm4jan292020.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 876,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F4 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F3 · balance_after: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 29, 2020 Filed Feb 3, 2020 21:14 UTC Amendment | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionSeries A Convertible Voting Preferred Stock · Derivative | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-000101 · sierraonco_fm4ajan312020.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 871,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F5 · shares: Consists of 11,500 shares of Series A Preferred Stock held by ABV VII which are convertible into an aggregate of 871,240 shares of Common Stock, as adjusted for the Reverse Split. F3 · price: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · derivative.exercise_date: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · derivative.expiration_date: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 29, 2020 Filed Feb 3, 2020 21:14 UTC Amendment | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionCommon Stock | 871,240 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-000101 · sierraonco_fm4ajan312020.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 876,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F4 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date. F3 · balance_after: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 21:39 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0000905718-19-000975 · sierraonco_fm4nov2019.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock $.001 par value · 60,000 shares Expires 2029-11-29 F1 · derivative.exercise_date: The option award was made in accordance with the terms of Sierra Oncology, Inc.'s 2015 Equity Incentive Plan (the "2015 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 29, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2015 Plan. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:01 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 2,300,000 | $1.20 | $2,760,000.00 |
DisclosureSEC source: 0000905718-19-000875 · soleno_fm4oct252019.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,969,272 F1 · ownership.nature: Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:39 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-016671 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 21:08 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000905718-18-000995 · soleno_fm4dec212018.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock $.001 par value · 20,000 shares Expires 2028-12-21 F3 · derivative.exercise_date: This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 21:08 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseWarrant · Derivative | 4,669,272 | $0.01 Strike: $2.00 | $28,949.49 |
DisclosureSEC source: 0000905718-18-000995 · soleno_fm4dec212018.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,669,272 Underlying: Common Stock $.001 par value · 233,463 shares Expires 2023-12-21 F1 · ownership.nature: Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 21:08 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 4,669,272 | $1.60 | $7,470,835.20 |
DisclosureSEC source: 0000905718-18-000995 · soleno_fm4dec212018.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,669,272 F1 · ownership.nature: Shares are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.